Literature DB >> 27580683

Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC.

Josep M Llovet1, Augusto Villanueva2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27580683     DOI： 10.1038/nrgastro.2016.140

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.

Authors:  Pei-Chien Tsai; Chung-Feng Huang; Ming-Lung Yu
Journal:  J Hepatol       Date:  2016-11-10       Impact factor: 25.083

3.  Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.

Authors:  Ju Dong Yang; Bashar A Aqel; Surakit Pungpapong; Gregory J Gores; Lewis R Roberts; Michael D Leise
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 25.083

4.  Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.

Authors:  Elisavet Serti; Xenia Chepa-Lotrea; Yun Ju Kim; Meghan Keane; Nancy Fryzek; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gastroenterology       Date:  2015-03-06       Impact factor: 22.682

5.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Authors:  Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti
Journal:  J Hepatol       Date:  2016-06-24       Impact factor: 25.083

6.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M Llovet
Journal:  Lancet Oncol       Date:  2015-09-08       Impact factor: 41.316

7.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Authors:  Anna S Lok; Leonard B Seeff; Timothy R Morgan; Adrian M di Bisceglie; Richard K Sterling; Teresa M Curto; Gregory T Everson; Karen L Lindsay; William M Lee; Herbert L Bonkovsky; Jules L Dienstag; Marc G Ghany; Chihiro Morishima; Zachary D Goodman
Journal:  Gastroenterology       Date:  2008-09-18       Impact factor: 22.682

Review 8.  Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391

9.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

Authors: 
Journal:  J Hepatol       Date:  2016-06-07       Impact factor: 25.083

10.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal; Graham R Foster; William L Irving
Journal:  J Hepatol       Date:  2016-07-05       Impact factor: 30.083
  10 in total
  34 in total

Review 1.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

2.  The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.

Authors:  Yuan-Hung Kuo; Jing-Houng Wang; Kuo-Chin Chang; Chao-Hung Hung; Sheng-Nan Lu; Tsung-Hui Hu; Yi-Hao Yen; Kwong-Ming Kee; Chien-Hung Chen
Journal:  Invest New Drugs       Date:  2019-11-08       Impact factor: 3.850

3.  Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.

Authors:  Zhenjuan Li; Haiping Gong; Qiuping Liu; Wanli Wu; Jianting Cheng; Yingyi Mei; Yaolong Chen; Hongjun Zheng; Xiaohong Yu; Shi Zhong; Yi Li
Journal:  Immunology       Date:  2020-01-10       Impact factor: 7.397

4.  Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus.

Authors:  M-L Plissonnier; T Lahlali; M Raab; M Michelet; C Romero-López; M Rivoire; K Strebhardt; D Durantel; M Levrero; P Mehlen; F Zoulim; R Parent
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

5.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

6.  De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.

Authors:  Allison J Kwong; W Ray Kim; Jennifer A Flemming
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

Review 7.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

8.  The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.

Authors:  Daniel Ferguson; Jun Zhang; Matthew A Davis; Robert N Helsley; Lise-Lotte Vedin; Richard G Lee; Rosanne M Crooke; Mark J Graham; Daniela S Allende; Paolo Parini; J Mark Brown
Journal:  J Lipid Res       Date:  2016-12-10       Impact factor: 5.922

9.  Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.

Authors:  Annsa C Huang; Neil Mehta; Jennifer L Dodge; Francis Y Yao; Norah A Terrault
Journal:  Hepatology       Date:  2018-05-16       Impact factor: 17.425

10.  HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Authors:  Solomon Owusu Sekyere; Bernhard Schlevogt; Friederike Mettke; Mohammad Kabbani; Katja Deterding; Thomas Christian Wirth; Arndt Vogel; Michael Peter Manns; Christine Susanne Falk; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Cancer       Date:  2018-07-18       Impact factor: 11.740
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.